New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For RHHBY;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
12:13 EDTGSKGlaxoSmithKline sees Novartis transaction closing next week
Subscribe for More Information
11:24 EDTGSKGlaxoSmithKline announces return of alli to retail stores
Subscribe for More Information
07:18 EDTRHHBYG Corp to hold annual meeting
Subscribe for More Information
06:14 EDTRHHBYPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
09:06 EDTRHHBYRoche receives orphan status for treatment of pemphigus vulgaris
The FDA granted Roche's Genentech unit orphan status for rituximab, its treatment of pemphigus vulgaris.
07:05 EDTRHHBYRoche and BioMed X enter collaboration agreement to develop sensor technology
Subscribe for More Information
February 23, 2015
13:33 EDTGSKRBS could name Howard Davies as chairman this week, FT reports
Royal Bank of Scotland (RBS) could name Howard Davies as its chairman as early as Thursday, when the bank reports its full-year results, the Financial Times reports. Davies is currently chairman of insurance business Phoenix Group and chairs Morgan Stanley's (MS) risk committee. Current RBS Chairman Philip Hampton is set to become GlaxoSmithKline's (GSK) chairman as early as this summer. Reference Link
11:17 EDTGSKFTC puts conditions on Novartis's proposed acquisition of GSK oncology drugs
According to the FTC, Global pharmaceutical company Novartis (NVS) has agreed to divest all assets related to its BRAF and MEK inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma (ARRY) to settle charges that Novartis’s $16B acquisition of GlaxoSmithKline’s (GSK) portfolio of cancer-treatment drugs would likely be anticompetitive...If the acquisition goes forward as proposed, Novartis would likely delay or terminate development of both its BRAF and MEK inhibitors, as well as the combination product. For that reason, Novartis’s acquisition of GSK’s portfolio of cancer-treatment drugs would likely cause significant competitive harm in the U.S. markets for both the BRAF and MEK inhibitors, ultimately raising prices for consumers and depriving them of potentially superior products. Under the terms of the proposed consent agreement, Novartis is required to provide transitional services to Array BioPharma to ensure that development of the BRAF and MEK inhibitors continues uninterrupted and that competition in BRAF and MEK inhibitor markets is not reduced. Reference Link
06:21 EDTRHHBYFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
February 20, 2015
16:48 EDTRHHBYDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
07:23 EDTGSK, RHHBYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTGSKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTRHHBYPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
09:09 EDTRHHBYLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
08:23 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
06:45 EDTRHHBYStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
05:31 EDTRHHBYExelixis announces acceptance of NDA for Genentech cobimetinib
Subscribe for More Information
05:26 EDTRHHBYFDA grants Genentech cobimetinib priority review for combination use
Subscribe for More Information
February 17, 2015
07:38 EDTGSKGlaxo replaces head of struggling U.S. drug unit, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use